Belhaven Biopharma
Chapel Hill, US · Founded 2020 · Delaware corporation
Belhaven Biopharma develops Nasdepi®, a dry powder epinephrine nasal spray for treating severe allergic reactions and anaphylaxis, offering a needle-free, shelf-stable alternative to traditional epinephrine auto-injectors. The product is currently in clinical trials and aimed at people with life-threatening allergies, including underserved regions where injectable epinephrine is unavailable or unreliable.
BiotechHealthtechMedical Devices
Founders & leadership
DA
David Algon NealChief Financial Officer and Secretary
SD
Scott David LymanPresident and Chief Executive Officer
WW
Wes WheelerDirector
DW
Derek WinstanlyDirector
Reported raises · per SEC filings
Form D private placements▶$32.3MraisedOct 2025 · 222 investors · PharmaceuticalsRule 506(b)
▶$32.3MraisedOct 2025 · 222 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Wes WheelerDirector
- David Algon NealExecutive Officer, Director
- Derek WinstanlyDirector
- Scott David LymanExecutive Officer, Director
- Offering amount
- $32.3M
- Amount sold
- $32.3M
- First sale
- Aug 2025
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.